Following a scientific review of the safety of pholcodine, the Medicines and Healthcare products Regulatory Agency (MHRA), with advice from the independent Commission on Human Medicines, has recommended that all pholcodine-containing cough and cold medicines should be withdrawn as a precautionary measure. 

Anaphylaxis UK is urging healthcare professionals to make sure that medication prescribed to their patients does not contain ingredients that they are allergic too.  

A review of recent data regarding frequency of allergic reactions has shown similar rates of anaphylaxis to COVID vaccines as to other vaccines.  

The Patient Information Forum (PIF) has today (28 February) launched a new PIF TICK toolkit to help healthcare professionals provide trusted information to their patients. 

A review of infant weaning research from around the world has concluded that the introduction of certain food allergens before the age of 11 months could decrease the likelihood of developing some food allergies. 

DBV Technologies has announced that the FDA has lifted the partial clinical hold on the company’s VITESSE trial.

Trends, drivers and future perspectives Food allergy can represent a serious human health issue. The observed rise in regional incidence and global prevalence of food allergies raise, among other, also questions about the risks related to the consumption of new,

The Scottish Medicines Consortium (SMC) has completed its assessment of Arachis hypogaea L., semen (peanuts) (Palforzia®),and have confirmed this is not recommended for use within NHSScotland. They concluded that  treatment with Palforzia® is expected to be resource intensive with food allergy

Anaphylaxis UK is deeply saddened to learn of the death of Frans Timmermans, founder of the Dutch Anaphylaxis Network.